Investor due diligence of a development-stage microbiome company

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....
Learn More

Investor Due Diligence: Pharma Business Development Case Studies

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...
Learn More

Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
Learn More

Pharmaceutical Licensing: Negotiation Support

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
Learn More

Due diligence: biologic technologies & phase III probability of success of CNS asset

Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
Learn More

Due diligence: plasma protein manufacturer; Phase III gene therapy asset

Case Study 1, Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in...
Learn More

Developing an independent market report for a cannabinoid company seeking a dual-listing

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
Learn More

Roadmap for commercial data infrastructure build to support rare disease drug launch

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...
Learn More

University life sciences IP and project portfolio review

Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...
Learn More

Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita was...
Learn More

Cell and gene therapy manufacturing facility planning

Challenge A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.
Learn More

Due diligence on a new medical imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More
1 2 3 4 5 ... 19
Next

Facing a complex life science challenge? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our life science consulting services

© 2019 Alacrita Holdings Limited   |  Life Science, Biotech & Pharmaceutical Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


303 Wyman Street
Waltham, MA
02451

Registered in Massachusetts.


Rue du Château 20
1814 La Tour-de-Peilz
Switzerland

Registered in Switzerland.
No. CHE-233.138.008